Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
Dr. Shah Highlights Immunotherapy for Esophageal Cancer
on July 18, 2018 at 1:58 pm
Manish A. Shah, MD, director of gastrointestinal oncology and chief of Solid Tumor Service at Weill Cornell Medicine/NewYork-Presbyterian Hospital, highlights immunotherapy for esophageal cancer. In g... […]
Survival Benefit From Immunotherapy With Modified Poliovirus in Recurrent Glioblastoma?
on July 18, 2018 at 11:22 am
“To mitigate this situation, we used bevacizumab to reverse edema rapidly and to treat symptoms. The role of bevacizumab in promoting immunotherapy mechanistically complicates preclinical evidence of ... […]
PolyU - Axis Therapeutics Joint Center for Immunotherapy Launched to Develop Innovative Cancer Treatments
on July 18, 2018 at 6:00 am
The Hong Kong Polytechnic University (PolyU) will join forces with Axis Therapeutics, a newly established joint venture by two global biopharmaceutical companies - Athenex, Inc. and Xiangxue Pharmaceu... […]
Immunotherapy Diversification: From CAR-T cells to CAR-NK cells
on July 17, 2018 at 10:45 pm
While at the time the mechanism was unknown, what became known as “Coley’s toxins” were really the beginnings of immunotherapy. Coley had noticed that patients with cancer who got infections after sur... […]
Dr. Hashmi on Immunotherapy in Prostate Cancer
on July 17, 2018 at 2:13 pm
Mehmood Hashmi, MD, assistant professor of medicine, University of Kansas Medical Center, discusses the use of immunotherapy in the treatment of patients with prostate cancer. As in many other cancers ... […]
Global Cancer Immunotherapy Market Analysis to 2022
on July 17, 2018 at 5:25 am
Immunotherapy is forecast to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. Multiple treat... […]
Killer immunotherapy—fighting cancer with genetic engineering
on July 17, 2018 at 4:13 am
Finding a cure for cancer is no easy feat, but Dr. Misty Jenkins has built her career in immunotherapy to do just that. Since 2016, Misty has led a lab at the Walter and Eliza Hall Institute of Medica... […]
News digest – immunotherapy for childhood cancer, glowing brain surgery, a new health secretary and CRISPR
on July 13, 2018 at 11:24 pm
A chemical dye that lights up brain tumours during surgery should be used more widely on the NHS in England, says NICE. The dye, called 5-amino levulinic acid (5-ALA), can help surgeons to distinguish ... […]
The Benihana of cancer vaccines: How are medical oncologists advancing immunotherapy?
on July 12, 2018 at 5:24 am
In a keynote presentation at the MedCity CONVERGE conference, medical oncologist Dr. Joshua Brody, the director of the lymphoma immunotherapy program at Icahn School of Medicine at Mount Sinai in New ... […]
EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, QARZIBA® (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma
on July 11, 2018 at 4:01 pm
HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunothera... […]
via Google News and Bing News